Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/sage/diagnostic-value-of-serum-dihydrodiol-dehydrogenase-2-levels-in-mpaD6YjPN2
References (20)
-
Chunhua Xu, Ke-ke Hao, Like Yu, Xiuwei Zhang (2014)
Serum interleukin-17 as a diagnostic and prognostic marker for non-small cell lung cancerBiomarkers, 19
-
M. Grunnet, J. Sørensen (2012)
Carcinoembryonic antigen (CEA) as tumor marker in lung cancer.Lung cancer, 76 2
-
N. Hsu, H. Ho, K. Chow, Tzei-Yi Lin, C. Shih, Liang‐Shun Wang, C. Tsai (2001)
Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer.Cancer research, 61 6
-
R. Siegel, K. Miller, A. Jemal (2015)
Cancer statistics, 2015CA: A Cancer Journal for Clinicians, 65
-
M. Ueda, Y. Hung, Jin-Tang Chen, S. Chiou, Hsuan-hua Huang, Tzei-Yi Lin, Y. Terai, K. Chow (2006)
Infection of human papillomavirus and overexpression of dihydrodiol dehydrogenase in uterine cervical cancer.Gynecologic oncology, 102 2
-
Robert Smith, V. Cokkinides, D. Brooks, D. Saslow, O. Brawley (2010)
Cancer Screening in the United States, 2010: A Review of Current American Cancer Society Guidelines and Issues in Cancer ScreeningCA: A Cancer Journal for Clinicians, 60
-
H. Deng, M. Adikari, H. Parekh, H. Simpkins (2004)
Ubiquitous induction of resistance to platinum drugs in human ovarian, cervical, germ-cell and lung carcinoma tumor cells overexpressing isoforms 1 and 2 of dihydrodiol dehydrogenaseCancer Chemotherapy and Pharmacology, 54
-
E. Kassis, A. Vaporciyan, S. Swisher, A. Correa, B. Bekele, J. Erasmus, W. Hofstetter, R. Komaki, R. Mehran, C. Moran, K. Pisters, D. Rice, G. Walsh, J. Roth (2009)
Application of the revised lung cancer staging system (IASLC Staging Project) to a cancer center population.The Journal of thoracic and cardiovascular surgery, 138 2
-
J. Mulshine, Daniel Sullivan (2005)
Clinical practice. Lung cancer screening.The New England journal of medicine, 352 26
-
Shaohua Ma, Lu-yan Shen, N. Qian, Ke-Neng Chen (2011)
The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited.Cancer biomarkers : section A of Disease markers, 10 3-4
-
Chunhua Xu, Zhihong Sheng, Huiying Hu, Ke-ke Hao, Qingbo Wang, Li-ke Yu (2014)
Elevated expression of Cripto-1 correlates with poor prognosis in non-small cell lung cancerTumor Biology, 35
-
T. Penning, Yi Jin, S. Steckelbroeck, T. Rižner, M. Lewis (2004)
Structure–function of human 3α-hydroxysteroid dehydrogenases: genes and proteinsMolecular and Cellular Endocrinology, 215
-
K. Okamura, K. Takayama, M. Izumi, T. Harada, K. Furuyama, Y. Nakanishi (2013)
Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer.Lung cancer, 80 1
-
Hung-Chi Chang, Yao-Li Chen, Chien-Pin Chan, K. Yeh, S. Kuo, C. Ko, H. Fang (2009)
Overexpression of Dihydrodiol Dehydrogenase as a Prognostic Marker in Resected Gastric Cancer PatientsDigestive Diseases and Sciences, 54
-
Peng Kuang, Caicun Zhou, Xue-Fei Li, S. Ren, Bing Li, Yongsheng Wang, Jiayu Li, Liang Tang, Jie Zhang, Yin-min Zhao (2012)
Proteomics-based identification of secreted protein dihydrodiol dehydrogenase 2 as a potential biomarker for predicting cisplatin efficacy in advanced NSCLC patients.Lung cancer, 77 2
-
R. Christenson (2008)
Preamble: National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for utilization of biomarkers in acute coronary syndromes and heart failure.Clinical biochemistry, 41 4-5
-
H. Tai, Torng-Sen Lin, Hsuan-hua Huang, Tzei-Yi Lin, M. Chou, S. Chiou, K. Chow (2007)
Overexpression of aldo-keto reductase 1C2 as a high-risk factor in bladder cancer.Oncology reports, 17 2
-
Chih‐Yi Chen, Chung-Ping Hsu, N. Hsu, C. Shih, Tzei-Yi Lin, K. Chow (2002)
Expression of dihydrodiol dehydrogenase in the resected stage I non-small cell lung cancer.Oncology reports, 9 3
-
Ling-jin Huang, Sheng-xi Chen, Yan Huang, W. Luo, Hai-he Jiang, Qing-hua Hu, Pengfei Zhang, Hong-Jun Yi (2006)
Proteomics-based identification of secreted protein dihydrodiol dehydrogenase as a novel serum markers of non-small cell lung cancer.Lung cancer, 54 1
-
R. Siegel, Jiemin Ma, Zhaohui Zou, A. Jemal (2014)
Cancer statistics, 2014CA: A Cancer Journal for Clinicians, 64
- Publisher
- SAGE
- Copyright
- © The Author(s) 2018
- ISSN
- 1724-6008
- DOI
- 10.1177/1724600818776832
- Publisher site
- See Article on Publisher Site
Abstract
Objectives:Dihydrodiol dehydrogenase 2 (DDH2) plays an important role in pathogenesis of non-small-cell lung cancer (NSCLC). This study aimed to evaluate the value of serum DDH2 levels in NSCLC patients.Methods:Serum samples were obtained from 863 NSCLC patients and 439 healthy controls. The samples were randomly divided into a training set and a test set. Serum DDH2 levels were assayed by enzyme-linked immunosorbent assay (ELISA).Results:The levels of DDH2 in NSCLC patients were significantly higher than those in healthy controls (P < 0.001). The diagnostic use of DDH2 in lung adenocarcinoma was significantly greater than that of carcinoembryonic antigen, cytokeratin 19 fragment (CYFRA21-1), and carbohydrate antigen 125 (P < 0.001). Combining DDH2 with carcinoembryonic antigen, CYFRA21-1, and carbohydrate antigen 125 was more effective for lung adenocarcinoma diagnosis than DDH2 alone. In addition, the levels of DDH2 could contribute to the diagnosis of lung squamous cell carcinoma.Conclusions:The measurement of serum DDH2 is a valuable diagnostic marker for NSCLC patients.
Journal
The International Journal of Biological Markers – SAGE
Published: Nov 1, 2018